4883 Stock Overview
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Modalis Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥77.00 |
| 52 Week High | JP¥336.00 |
| 52 Week Low | JP¥77.00 |
| Beta | 0.22 |
| 1 Month Change | -16.30% |
| 3 Month Change | -32.46% |
| 1 Year Change | -71.38% |
| 3 Year Change | -95.77% |
| 5 Year Change | n/a |
| Change since IPO | -96.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4883 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -3.8% | 3.0% | 1.8% |
| 1Y | -71.4% | -24.6% | 31.0% |
Return vs Industry: 4883 underperformed the JP Biotechs industry which returned -24.6% over the past year.
Return vs Market: 4883 underperformed the JP Market which returned 31% over the past year.
Price Volatility
| 4883 volatility | |
|---|---|
| 4883 Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4883's share price has been volatile over the past 3 months.
Volatility Over Time: 4883's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Haruhiko Morita | modalistx.com |
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd.
Modalis Therapeutics Corporation Fundamentals Summary
| 4883 fundamental statistics | |
|---|---|
| Market cap | JP¥2.63b |
| Earnings (TTM) | -JP¥2.39b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs 4883 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4883 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥2.39b |
| Earnings | -JP¥2.39b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -69.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 29.9% |
How did 4883 perform over the long term?
See historical performance and comparison